ONO PHARMA USA’s Post

📢 Exciting News! Biophytis SA has entered into an exclusive license agreement with Blanver, a top pharmaceutical company in Brazil, to develop and commercialize their lead drug candidate, BIO101, across Latin America, including Brazil, Mexico, Argentina, and Colombia. Biophytis will receive an upfront payment of €1 million and potential milestone payments up to €107 million, dependent on regulatory and commercial success. Blanver will manage the development, registration, and commercialization efforts in these regions. BIO101, an orally administered small molecule, aims to enhance muscle function in patients with age-related muscle disorders like sarcopenia and Duchenne muscular dystrophy. Promising results from preclinical and clinical studies highlight its potential to improve muscle strength and mobility. This partnership is a major step forward, addressing the unmet medical needs for age-related muscle disorders in Latin America and further establishing Biophytis' innovative approach in the biotechnology industry. Read the full article at https://lnkd.in/eW4TqvfE

Biopharmaceuticals are complex molecules produced through living cells or organisms and are mainly therapeutic proteins to treat life threatening diseases. 🧪 They represent a significant and growing portion of the pharmaceutical market, with a project global market size of over $400 billion by 2025. 📈 Dr Verónica Martínez is one of our AQ Industry Research Fellowship recipients and is working to develop a novel platform to guide the design of cell factories for complex proteins. 👏 Over three years, Dr Martínez will receive $360,000 to put towards reducing the cost of biopharmaceutical production, enabling the affordability of treatments for serious diseases. 🔍 "This project will contribute to making advanced therapeutic products easily available to people who need it" said Dr Martínez. 💬 The Advance Queensland Industry Research Fellowships program supports researchers partnering with industry to complete original research that will have a positive impact on Queensland. 💪 Applications for our 2024 Industry Research Fellowship grants are now open and close on the 22nd April! 🏃♂️ For information on how to apply, guidelines and more 👇 https://bit.ly/3zZ5d2K The University of Queensland #AdvanceQld  #QldInnovation #AQIndustryResearchFellowships

💡 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 that to date, EU member states have provided relatively little insight into how they plan to integrate the EU HTA outputs into national processes? In our latest article, Analyst Vishal Chanda explores which member states have made statements on how national HTA may or may not be adapted considering the EU HTA. 📖 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://lnkd.in/eAGcKvHY This read is essential for anyone in the pharmaceutical and biotech sectors aiming to successfully navigate the complexities of HTA 🚀 #Pharma #Biotech #MarketAccess #HTA #EUHTA #PatientAccess #JCA #Oncology

Ono Pharmaceuticals partners with InveniAI for AI-driven therapeutic target identification. #PharmaAI 🤝 Follow us on Discord 🔜: https://lnkd.in/gt823Zd3 🤝 Follow us on Whatsapp 🔜 https://wapia.in/wabeta _ ❇️ Summary: Ono Pharmaceutical Co. Ltd. has partnered with InveniAI LLC to use artificial intelligence and machine learning to identify new therapeutic targets for multiple diseases. InveniAI will utilize its AI drug discovery platforms to propose drug discovery hypotheses for optimization, which Ono will then validate through validation studies. Ono will have exclusive rights to develop and commercialize any drug candidates generated through this collaboration. This partnership aims to improve the efficiency of drug discovery research and provide innovative therapeutic options to patients worldwide. Hashtags: #chatGPT 1. #InveniAI 2. #AIinPharmaceuticals

Clinical Trial: Topical Application of CBD Mitigates Neuropathy The topical administration of CBD oil is associated with reduced pain in patients with peripheral neuropathy, according to clinical trial data published in the journal Current Pharmaceutical Biotechnology. A team of investigators affiliated with Scripps Mercy Hospital in San Diego and Des Moines University in Iowa assessed the efficacy of topically delivered CBD oil in the management of neuropathic pain in a randomized, placebo-controlled clinical trial. Twenty-nine patients participated in the study. Each patient received both treatment and placebo at various intervals of the four-week trial. #cannabis #medicalcannabis #neuropathicpain #cbd

📊🔬 Dive into the world of estimands in oncology with two esteemed statisticians! 🌟 Evgeny Degtyarev and Kaspar Rufibach. Don't miss out on this insightful conversation!

Apply to present at the FOP Drug Development Forum (June 26-28 in Stockholm, Sweden as well as virtually). The DDF features 12-minute "FOP Talks" grouped in sessions that cover learnings from clinical trials, observational research, and rational drug design. This year’s event includes a session on untargeted discovery in FOP. Apply to do a platform presentation and/or a poster with unpublished data or data not published before January 1, 2024: https://lnkd.in/dfrq8sYC Deadline is February 19. The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf

📢 New publication from the European Lead Factory! The paper titled "The European Lead Factory: results from a decade of collaborative, public–private, drug discovery programs" reviews the outcomes of the European Lead Factory (ELF) and discusses its unique compound-sharing model, its extensive library, and the screening of these compounds against various targets and phenotypic assays. The ELF facilitated the identification of compounds leading to patents and spin-off companies. The paper highlights the significant impact of this model in drug discovery, emphasizing its potential for future pharmaceutical research and development. Key Highlights: - Creation of a unique compound library through an innovative sharing model - Extensive screening of compounds against diverse targets and assays - Significant outcomes: patents, publications, spin-off companies, and clinical trials The ELF model demonstrates the power of collaborative efforts to advance pharmaceutical research. It's a testament to how shared resources and expertise can lead to remarkable achievements in the discovery of new medicines. Read the full paper for more insights in Drug Discovery Today 👇 #DrugDiscovery #Innovation #Collaboration #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 Joint Undertaking (Innovative Health Initiative (IHI)). Herman van Vlijmen, Andrew D. Pannifer, Phil Cochrane, Daniel Basting, Volkhart Li (PhD), Ola Engkvist, Jean-Yves Ortholand, Markus Wagener, James Duffy, Dirk Finsinger, Jeremy Davis, Steven van Helden, Jon de Vlieger, Bayer, Grünenthal Group, Servier, The Janssen Pharmaceutical Companies of Johnson & Johnson, AstraZeneca, Merck Group, Sanofi, UCB, Lygature, BioAscent, EDELRIS, Symeres, Pivot Park Screening Centre, Sygnature Discovery, Taros Chemicals, National Phenotypic Screening Centre, University of Dundee, University of Oxford, Medicines for Malaria Venture,

The Drug Development Forum is a great opportunity to meet and engage with the different stakeholders in FOP research. Check out this quick recap from the DDF back in 2019 to get a sense of what to expect in Stockholm this June: https://lnkd.in/dvmhQRy6 Learn more and register: ifopa.org/2024_fop_ddf The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options.

【KBIC Company Topic】 United Immunity’s UI-101 has been selected by AMED as “Strengthening Program for Pharmaceutical Startup Ecosystem” (Published: December 5, 2023) United Immunity’s UI-101 has been selected by AMED as “Strengthening Program for Pharmaceutical Startup Ecosystem”. This program would give us step by step financial support (total double digit million dollars expected) from preclinical to human proof of concept studies. UI-101 is a potential best in class systemic immune modulator leveraging our Myeloid Targeting PlatformTM to treat patients suffering from cold tumors. We are thankful for all of our supporters. Read more: https://lnkd.in/dB9ZVXd6 #kbic #fbri #kobe #kansai #japan #innovation #openinnovation #ecosystem #lifescience #cluster #nanotechnology #immunotherapy #solidtumors #infectiousdiseases